These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38603681)

  • 1. Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    Pastrovic F; Novak R; Grgurevic I; Hrkac S; Salai G; Zarak M; Grgurevic L
    PLoS One; 2024; 19(4):e0301416. PubMed ID: 38603681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
    J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
    J Hepatol; 2024 May; ():. PubMed ID: 38823501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
    Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
    Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive tests for clinically significant portal hypertension after HCV cure.
    Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
    J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient].
    Jiang FR; Yan HD
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):995-1000. PubMed ID: 34814395
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
    Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
    Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
    Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
    Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
    Wong YJ; Zhaojin C; Tosetti G; Degasperi E; Sharma S; Agarwal S; Chuan L; Huak CY; Jia L; Xiaolong Q; Saraya A; Primignani M
    Clin Mol Hepatol; 2023 Jan; 29(1):135-145. PubMed ID: 36064306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.
    Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis.
    Liu S; Ma J; Chen P; Liu S; Guo Y; Tan M; Guo X; Feng Y; Wang Q; Li W; Yang C; Gao B; Hua Y; Liu N; Song H; He R; Wang R; Gao Q; Liu C; Qi X
    J Med Virol; 2024 Jan; 96(1):e29380. PubMed ID: 38235849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model.
    Wang C; Huang Y; Liu C; Liu F; Hu X; Kuang X; An W; Liu C; Liu Y; Liu S; He R; Wang H; Qi X
    Radiology; 2023 Apr; 307(2):e221648. PubMed ID: 36719293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
    Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
    Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
    Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
    J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous motion of liver correlates to the severity of portal hypertension.
    Gelman S; Sakalauskas A; Zykus R; Pranculis A; Jurkonis R; Kuliavienė I; Lukoševičius A; Kupčinskas L; Kupčinskas J
    World J Gastroenterol; 2020 Oct; 26(38):5836-5848. PubMed ID: 33132638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.